283 related articles for article (PubMed ID: 34586829)
1. A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models.
Yu X; Li D; Kottur J; Shen Y; Kim HS; Park KS; Tsai YH; Gong W; Wang J; Suzuki K; Parker J; Herring L; Kaniskan HÜ; Cai L; Jain R; Liu J; Aggarwal AK; Wang GG; Jin J
Sci Transl Med; 2021 Sep; 13(613):eabj1578. PubMed ID: 34586829
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
[TBL] [Abstract][Full Text] [Related]
3. Discovery of
Chen W; Chen X; Li D; Zhou J; Jiang Z; You Q; Guo X
J Med Chem; 2021 Jun; 64(12):8221-8245. PubMed ID: 34105966
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.
Li D; Yu X; Kottur J; Gong W; Zhang Z; Storey AJ; Tsai YH; Uryu H; Shen Y; Byrum SD; Edmondson RD; Mackintosh SG; Cai L; Liu Z; Aggarwal AK; Tackett AJ; Liu J; Jin J; Wang GG
Oncogene; 2022 Jun; 41(24):3328-3340. PubMed ID: 35525905
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5.
Senisterra G; Wu H; Allali-Hassani A; Wasney GA; Barsyte-Lovejoy D; Dombrovski L; Dong A; Nguyen KT; Smil D; Bolshan Y; Hajian T; He H; Seitova A; Chau I; Li F; Poda G; Couture JF; Brown PJ; Al-Awar R; Schapira M; Arrowsmith CH; Vedadi M
Biochem J; 2013 Jan; 449(1):151-9. PubMed ID: 22989411
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
Grebien F; Vedadi M; Getlik M; Giambruno R; Grover A; Avellino R; Skucha A; Vittori S; Kuznetsova E; Smil D; Barsyte-Lovejoy D; Li F; Poda G; Schapira M; Wu H; Dong A; Senisterra G; Stukalov A; Huber KVM; Schönegger A; Marcellus R; Bilban M; Bock C; Brown PJ; Zuber J; Bennett KL; Al-Awar R; Delwel R; Nerlov C; Arrowsmith CH; Superti-Furga G
Nat Chem Biol; 2015 Aug; 11(8):571-578. PubMed ID: 26167872
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction.
Karatas H; Li Y; Liu L; Ji J; Lee S; Chen Y; Yang J; Huang L; Bernard D; Xu J; Townsend EC; Cao F; Ran X; Li X; Wen B; Sun D; Stuckey JA; Lei M; Dou Y; Wang S
J Med Chem; 2017 Jun; 60(12):4818-4839. PubMed ID: 28603984
[TBL] [Abstract][Full Text] [Related]
8. WDR5 interacts with mixed lineage leukemia (MLL) protein via the histone H3-binding pocket.
Song JJ; Kingston RE
J Biol Chem; 2008 Dec; 283(50):35258-64. PubMed ID: 18840606
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer.
Yu X; Li D; Kottur J; Kim HS; Herring LE; Yu Y; Xie L; Hu X; Chen X; Cai L; Liu J; Aggarwal AK; Wang GG; Jin J
J Med Chem; 2023 Dec; 66(23):16168-16186. PubMed ID: 38019706
[TBL] [Abstract][Full Text] [Related]
10. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
Alicea-Velázquez NL; Shinsky SA; Loh DM; Lee JH; Skalnik DG; Cosgrove MS
J Biol Chem; 2016 Oct; 291(43):22357-22372. PubMed ID: 27563068
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.
Li DD; Wang ZH; Chen WL; Xie YY; You QD; Guo XK
Bioorg Med Chem; 2016 Nov; 24(22):6109-6118. PubMed ID: 27720555
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.
Chen W; Chen X; Li D; Wang X; Long G; Jiang Z; You Q; Guo X
Eur J Med Chem; 2021 Nov; 223():113677. PubMed ID: 34225179
[TBL] [Abstract][Full Text] [Related]
13. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction.
Karatas H; Townsend EC; Cao F; Chen Y; Bernard D; Liu L; Lei M; Dou Y; Wang S
J Am Chem Soc; 2013 Jan; 135(2):669-82. PubMed ID: 23210835
[TBL] [Abstract][Full Text] [Related]
14. The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening.
Ye X; Zhang R; Lian F; Zhang W; Lu W; Han J; Zhang N; Jin J; Luo C; Chen K; Ye F; Ding H
Bioorg Med Chem Lett; 2019 Feb; 29(4):638-645. PubMed ID: 30626558
[TBL] [Abstract][Full Text] [Related]
15. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.
Zhang X; Zheng X; Yang H; Yan J; Fu X; Wei R; Xu X; Zhang Z; Yu A; Zhou K; Ding J; Geng M; Huang X
Cancer Lett; 2018 Sep; 431():150-160. PubMed ID: 29857126
[TBL] [Abstract][Full Text] [Related]
16. Structure of WDR5 bound to mixed lineage leukemia protein-1 peptide.
Patel A; Dharmarajan V; Cosgrove MS
J Biol Chem; 2008 Nov; 283(47):32158-61. PubMed ID: 18829459
[TBL] [Abstract][Full Text] [Related]
17. The Development of Inhibitors Targeting the Mixed Lineage Leukemia 1 (MLL1)-WD Repeat Domain 5 Protein (WDR5) Protein- Protein Interaction.
Ye X; Chen G; Jin J; Zhang B; Wang Y; Cai Z; Ye F
Curr Med Chem; 2020; 27(33):5530-5542. PubMed ID: 31132972
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.
Li DD; Chen WL; Xu XL; Jiang F; Wang L; Xie YY; Zhang XJ; Guo XK; You QD; Sun HP
Eur J Med Chem; 2016 Aug; 118():1-8. PubMed ID: 27116709
[TBL] [Abstract][Full Text] [Related]
19. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
20. GRWD1-WDR5-MLL2 Epigenetic Complex Mediates H3K4me3 Mark and Is Essential for Kaposi's Sarcoma-Associated Herpesvirus-Induced Cellular Transformation.
Wei S; Lu S; Liang L; Wang X; Li W; Li T; Chen L; Ju E; Zhang X; Lai Z; Huang Y; Lu X; Gao SJ
mBio; 2021 Dec; 12(6):e0343121. PubMed ID: 34933446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
